Under construction – not a live service
Sign in
Taking people in ChinaNo phase

Studies how axial spondyloarthritis changes over time in Chinese patients

Follows people with axial spondyloarthritis to track changes in disease activity and function.

Plain-language title generated from the registry record
Registry title: The Disease Progression of Chinese Axial Spondyloarthritis in a Real-word Cohort Study

Key facts

Where
Beijing, ChinaSee the site

Where in China

  • China-Japan Friendship HospitalBeijing, ChinaTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
China-Japan Friendship Hospital
Trial code
NCT06844643
Record updated
13 April 2026
Original description
An observational, ambispective cohort to learn about the disease progression of axial spondyloarthritis (axSpA) according to the changes from baseline in measures of disease activity, function, and imaging.Read full original descriptionShow less

The Disease Progression of Chinese Axial Spondyloarthritis in a Real-word Cohort Study

An observational, ambispective cohort to learn about the disease progression of axial spondyloarthritis (axSpA) according to the changes from baseline in measures of disease activity, function, and imaging.

Inclusion: Patients aged 18 years or older; Diagnosis of axial spondyloarthritis (axSpA) according to the Assessment of Spondyloarthritis International Society (ASAS) classification criteria.

Exclusion: Current diagnosis of schizophrenia, other psychotic disorders, severe cognitive impairment, or epilepsy with recurrent uncontrolled seizures, which, in the opinion of the investigator, may impair the ability to provide informed consent or comply with follow-up visits; Presence of severe, unstable medical conditions that may interfere with the study assessments, including but not limited to:; End-stage renal disease (eGFR < 30 mL/min/1.73m²) Severe cardiovascular disease Active malignancy or malignancy requiring ongoing treatment; Pregnant or lactating women.

ClinicalTrials.gov NCT06844643